ECM
VKTX icon

ExodusPoint Capital Management’s Viking Therapeutics VKTX Stock Holding History

ExodusPoint Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
361,126
+291,499
+419% +$9.42M 0.09% 212
2026
Q1 		$2.27M Sell
69,627
-652,572
-90% -$21M 0.02% 742
2025
Q4 		$25.4M Buy
722,199
+518,009
+254% +$18.4M 0.2% 70
2025
Q3 		$5.37M Buy
204,190
+165,474
+427% +$4.94M 0.05% 385
2025
Q2 		$1.03M Sell
38,716
-311,094
-89% -$8.19M 0.01% 956
2025
Q1 		$8.45M Buy
349,810
+114,307
+49% +$3.61M 0.08% 248
2024
Q4 		$9.48M Sell
235,503
-27,656
-11% -$1.58M 0.07% 284
2024
Q3 		$16.7M Buy
263,159
+210,229
+397% +$12.3M 0.1% 160
2024
Q2 		$2.81M Buy
52,930
+38,835
+276% +$2.55M 0.02% 654
2024
Q1 		$1.16M Sell
14,095
-53,734
-79% -$2.39M 0.01% 896
2023
Q4 		$1.26M Buy
+67,829
New +$887K 0.01% 733
2022
Q4 		– Sell
-30,753
Closed -$84K – 2169
2022
Q3 		$84K Buy
30,753
+6,512
+27% +$21.3K ﹤0.01% 1762
2022
Q2 		$70K Buy
+24,241
New +$60K ﹤0.01% 1774
2021
Q4 		– Sell
-24,405
Closed -$153K – 2626
2021
Q3 		$153K Sell
24,405
-51,235
-68% -$317K ﹤0.01% 1833
2021
Q2 		$453K Buy
75,640
+16,357
+28% +$97.1K 0.01% 1503
2021
Q1 		$375K Buy
+59,283
New +$417K 0.01% 1532
2020
Q3 		– Sell
-26,469
Closed -$191K – 2259
2020
Q2 		$191K Buy
+26,469
New +$176K 0.01% 1530
2020
Q1 		– Sell
-20,102
Closed -$161K – 1669
2019
Q4 		$161K Sell
20,102
-15,502
-44% -$113K ﹤0.01% 1377
2019
Q3 		$245K Buy
35,604
+17,966
+102% +$133K 0.01% 1007
2019
Q2 		$146K Buy
+17,638
New +$151K 0.01% 984

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ExodusPoint Capital Management's VKTX Position: Q2 2026 in Review

ExodusPoint Capital Management increased its Viking Therapeutics (VKTX) stake by 419% in Q2 2026, buying an estimated $9.42M and bringing the position to 361,126 shares worth $14.1M. The position accounts for 0.09% of the portfolio, ranked #212.

ExodusPoint Capital Management first reported a position in VKTX in Q2 2019 and has held it in 20 quarters since. The position peaked at $25.4M in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • ExodusPoint Capital Management held 361,126 shares of Viking Therapeutics worth $14.1M as of Q2 2026.
  • ExodusPoint Capital Management bought 291,499 Viking Therapeutics shares in Q2 2026, an estimated $9.42M.
  • Viking Therapeutics made up 0.09% of ExodusPoint Capital Management's portfolio in Q2 2026, its #212 holding.
  • ExodusPoint Capital Management first reported a position in Viking Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • ExodusPoint Capital Management's Viking Therapeutics position peaked at $25.4M in Q4 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.